-
The Centers for Medicare & Medicaid Services (CMS) has proposed new rules for hospitals that would protect patients' right to choose their own visitors during a hospital stay, including visitors who are same-sex domestic partners, according to CMS.
-
-
There's no doubt that the debate over abortion is an integral part of not only family-centered discussions, but also the debates that occur on the left, on the right, and various points in the center on the political continuum.
-
A study published in the August issue of Health Affairs suggests that there are no differences in patient outcomes when anesthesia services are provided by certified registered nurse anesthetists (CRNAs), physician anesthesiologists, or supervised by physicians, according to the American Association of Nurse Anesthetists (AANA) in Park Ridge, IL.
-
The addition of CACS to a prediction model based upon the traditional risk factors significantly improved the classification of risk and helped to place more individuals in their appropriate risk categories.
-
The ECG shown above was obtained from a 77-year-old woman with chest discomfort and a permanent pacemaker. Do you see any abnormality on this paced tracing?
-
Aggressive approach to CVD reduces MI, folic acid and vitamin B12 for CAD, corticosteroids for acute exacerbations of COPD, prescription drug abuse among young adults, and ARBs and cancer risk.
-
A systematic review of 9 studies showed that the COX-2 inhibitor celecoxib and ibuprofen cause less upper GI bleeding than other NSAIDs. Diclofenac, meloxicam, ketoprofen, indomethacin, and naproxen have intermediate risk. Piroxicam and ketorolac have the highest risk. In general, drugs that have a long half-life or slow-release formulation have the greatest risk of GI bleeding.
-
There is no difference in rates of treatment failure, death, or readmission for COPD between patients treated with oral or intravenous steroids for exacerbation of COPD, but the IV route may be associated with increased cost and length of stay.
-
The first receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor has been approved for the treatment of osteoporosis.
